Ceregene - Newsroom

Ceregene Press Releases

04.19.13	Ceregene Reports Data From Parkinson's Disease Phase 2b Study
03.13.13	Ceregene and Alzheimer's Disease Cooperative Study Group Complete Enrollment of CERE-110 Phase 2 Trial
05.17.12	Ceregene Parkinson's Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
05.09.12	Parkinson's Disease therapeutics focal point at this year's ASGCT meeting
12.01.11	Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease
02.15.11	Ceregene Reports New Findings Regarding How Parkinson's Brains Respond to Neurotrophic Factors
02.03.11	Ceregene Advances Phase2b CERE-120 (AAV2-Neurturin) Trial in Parkinson's Disease
11.11.10	Ceregene Raises $11.5 Million in Series D Financing
10.19.10	Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
06.22.10	The Michael J. Fox Foundation Awards $2.5 Million to Support Ceregene's New Phase 2 Neurturin Clinical Study for Parkinson's Disease
04.28.10	Ceregene Has Initiated a New Phase 1/2 Trial of CERE-120 for Parkinson's Disease
08.05.09	Ceregene Receives Additional Grant from Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
05.27.09	Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
11.26.08	Ceregene Announces Clinical Data from Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease
11.04.08	Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant from National Institutes of Health
04.23.08	Ceregene Announces Two Key Additions to Leadership Team
01.07.08	Ceregene to Present at JPMorgan 26th Annual Healthcare Conference
12.12.07	Ceregene Presents Long-Term Follow-Up from Phase 1 Trial of CERE-120 in Parkinson's Disease
12.06.07	Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
11.14.07	Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
06.21.07	Ceregene and Genzyme Announce Partnership for the Development and Commercialization of CERE-120 for Parkinson's Disease
05.02.07	Ceregene Presents Interim Phase I Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
04.16.07	Ceregene Presents Long Term Follow-Up Data from Phase I Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

Archived Press Releases:

2006 | 2005 | 2004 | 2003 | 2002 | 2001

For media related questions or to request information, please send an e-mail to media@ceregene.com